Phospho-CDK1/2/3/5 (Tyr15) Antibody

Skip to product information
1 of 1

Selleck Chemicals

SKU:F2387-20UL

Regular price €199,00 EUR
Regular price Sale price €199,00 EUR
Sale Sold out
Taxes included. Shipping calculated at checkout.
Size
Quantity
View full details

About the Target

Phospho-CDK1/2/3/5 (Tyr15) is a target of interest in many antibody-based workflows. Cyclin-dependent kinases (CDKs) play a pivotal role in various essential cellular processes, including cell cycle regulation, transcription, communication, metabolism, and apoptosis. These kinases operate in a tightly controlled pathway to ensure accurate DNA replication and equal segregation during cell division. Disruption of these processes can lead to apoptosis; however, if left uncorrected, such deregulation may result in diseases like cancer, neurodegenerative disorders, and stroke. Depending on the literature source, Phospho-CDK1/2/3/5 (Tyr15) may also be discussed as Phospho-CDK1/2/3/5 (Tyr15).

Reported cellular context includes cytoplasm, cytoskeleton, endosome, and nucleus, which can matter when signal is compared across treatments or changing cell states. Following Phospho-CDK1/2/3/5 (Tyr15) across matched perturbations can help separate abundance effects from shifts in localization, complex assembly, or pathway state. In practice, this target is often considered at the family or isoform-group level, so experimental interpretation benefits from matched controls and clear comparison logic.

Research Context

Phospho-CDK1/2/3/5 (Tyr15) is commonly interpreted in the context of neuroscience and cell cycle research, and readouts are often stronger when a study separates expression changes from compartment-level redistribution. When reported signal spans cytoplasm, cytoskeleton, and endosome, a defined reference condition can make comparisons more interpretable across perturbations, passages, or replicate sets.

Consider these angles when interpreting target-level changes:

  • apparent redistribution between cytoplasm, cytoskeleton, and endosome across matched conditions
  • compartment-specific patterns relevant to neuronal polarity, transport, or synaptic context
  • cell-cycle linked differences in abundance, timing, or compartmental enrichment
  • differences between total target abundance and site-specific regulation when modified forms are compared

Variant Considerations

If your project spans exploratory questions, the regular version offers a balanced option for establishing baseline signal behavior for Phospho-CDK1/2/3/5 (Tyr15). This can help when protocols evolve over time and the goal is to compare experiments using a stable reference workflow.

Standardize sampling time, control choice, and downstream analysis thresholds so apparent differences in Phospho-CDK1/2/3/5 (Tyr15) reflect biology rather than handling. When interpreting Phospho-CDK1/2/3/5 (Tyr15), it is often useful to decide early whether the main question is overall abundance, compartmental enrichment, or context-dependent redistribution.

For multi-run studies, a shared reference condition can keep Phospho-CDK1/2/3/5 (Tyr15) trends easier to compare across datasets. That kind of consistency is especially helpful when follow-up work expands to new perturbations, model systems, or longitudinal collections.

Targets:
CDK1 • CDK2 • CDK3 • CDK5
Research Area:
Cell Cycle • Neuroscience
Application:
IHC • IP • WB
Reactivity:
Human • Rat
Specificity:
Phospho-CDK1/2/3/5 (Tyr15) Antibody [B6L9] recognizes endogenous levels of CDK1, CDK2, CDK3 and CDK5 protein only when phosphorylated at Y15.
Host:
Rabbit
Clonality:
Monoclonal
Clone:
B6L9
UniProt:
P24941P20248P24864
Storage Buffer:
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN₃
Storage Temperature:
-20°C

For Research Use Only. Not intended for diagnostic or therapeutic use.
Products may be subject to intellectual property rights.

The purchase of this product does not grant any license for commercial use, manufacturing, or clinical applications. The user is responsible for ensuring compliance with applicable laws and third-party rights.